Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That ...Middle East

SAN FRANCISCO and SUZHOU, China, April 6, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other...

Hence then, the article about innovent announces the approval of pemazyre pemigatinib by the nmpa for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fgfr2 fusion or rearrangement as confirmed by a validated diagnostic test that was published today ( Wednesday 06/04/2022 - 07:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That )

Also on site :

• Iconic Revenge Song, Ranked Among ‘Best Breakup Songs of All Time,’ Was Originally Written for Gretchen Wilson
• Quote Of The Day By Tom Hardy: 'There's Nothing Worse Than Anticipation. It's Always The Killer Of Everything. The Actuality Of...'
• Tom Cruise Says Taylor Swift Was ‘Schooling Me on Football’ at Chiefs Game, Calls Her a ‘Brilliant Musician and Director’